Williamson Z. Bradford, M.D., Ph.D.
Dr. Bradford brings over 25 years of experience in clinical research, including 19 years in the biopharma industry in executive, development, and medical affairs roles. He was a co-founder of Cascadia Therapeutics, which was acquired by Indalo in 2016, and recently served as the Chief Medical Officer of Moerae Matrix. Dr. Bradford was Senior Vice President of Clinical Development at InterMune, where he was the architect of the Esbriet® clinical program and approvals for idiopathic pulmonary fibrosis. He has also held positions at IntraBiotics Pharmaceuticals and Genentech. Dr. Bradford trained in internal medicine and infectious diseases and practiced academic medicine at the University of California, San Francisco. He received his Ph.D. in epidemiology from the University of California, Berkeley, his M.D. from the University of North Carolina, Chapel Hill, and his B.A. from Williams College.
Karl J. Kossen, Ph.D.
Dr. Kossen has 15 years of experience in pharmaceutical research, including drug discovery, drug development, and the characterization of disease biology. Dr. Kossen was previously Vice President of Disease Biology at InterMune, where he focused on the detailed profiling of anti-fibrotic drugs and biomarkers of fibrotic disease. He also facilitated external collaborations to further elucidate the pathobiology of idiopathic pulmonary fibrosis. Following the acquisition of InterMune by Roche in 2014, Dr. Kossen co-founded Blade Therapeutics and served as Senior Vice President of Biology. His efforts at Blade helped advance the therapeutic discovery pipeline and enable a $45M capital raise. Dr. Kossen received his B.S. in Chemistry and Cell & Molecular Biology from the University of Michigan and his Ph.D. in Biochemistry from the University of Colorado.
George H. Capps, M.S., M.B.A.
Mr. Capps brings to Indalo a track record of operational management, business development, and capital-raising success. He previously served as Director of Business Operations at Vasculox and as Director of Business Development at Mencuro Therapeutics. In all, he has contributed to the raising of well over $30 million in Seed and Series A funding for biopharmaceutical ventures. Prior to these operational roles, Mr. Capps provided management consulting services for biotechnology clients as part of the Strategy & Portfolio Analysis Practice of IMS Health. He received B.S. and M.S. degrees in the Biological Sciences and an M.B.A. from Stanford University.
Scott D. Seiwert, Ph.D.
Dr. Seiwert has 17 years of experience in the pharmaceutical industry, focused on drug discovery, preclinical development, and first-in-human clinical studies. Most recently, he served as Senior Vice President of Research and Technical Development at InterMune, where he was also a member of the Executive Committee, until its acquisition by Roche in 2014. In this capacity, he supported all nonclinical aspects of the anti-fibrotic drug Esbriet® in relation to its approval by the FDA and EMEA. Dr. Seiwert was also a scientific co-founder of Alios Biopharma, which was sold to Johnson & Johnson in that same year. Prior to these roles, he served as Director of Research at Sirna Therapeutics. Dr. Seiwert holds a Ph.D. in Molecular Biophysics and Biochemistry from Yale University School of Medicine.
Ramachandran Radhakrishnan, Ph.D.
Dr. Radhakrishnan has over 30 years of biopharmaceutical product development experience, with expertise in formulations, drug delivery, process development, manufacturing, and commercialization. He was previously Vice President of Pharmaceutical Product Development at InterMune, where he had responsibility for all CMC-related activities for multiple drugs, including pirfenidone (Esbriet®) for pulmonary fibrosis. Dr. Radhakrishnan has authored over 50 scientific publications and is a named inventor on 25 patents and patent applications. He received his B.S. and M.S. degrees in Chemistry from the University of Madras, earned his Ph.D. in Organic Chemistry from Wayne State University, and conducted postdoctoral training in Bioorganic Chemistry at MIT.
Board of Directors
Peter Barrett, Ph.D.
Dr. Barrett is a Partner at Atlas Venture, where he has been involved in the creation of numerous novel therapeutic and drug-discovery platform companies. He was instrumental in the sales of Stromedix to Biogen and Novamed to SciClone Pharmaceuticals and is currently chairman of Obsidian Therapeutics, Synlogic, and Zafgen. Prior to joining Atlas in 2002, Dr. Barrett was Co-Founder, Executive Vice President, and Chief Business Officer of Celera Genomics, which completed the first successful sequencing of the human genome. He is currently Vice Chairman of the Advisory Council and Adjunct Professor at the Barnett Institute of Chemical and Biological Analysis at Northeastern University and a member of the research council at Boston Children’s Hospital. He received his B.S. in Chemistry from Lowell Technological Institute and his Ph.D. in Analytical Chemistry from Northeastern University.
Rajesh Devraj, Ph.D.
Dr. Devraj has 20 years of pharmaceutical industry experience in drug discovery, preclinical and early clinical development, business development, and R&D strategy. He currently serves as Co-Founder and CSO of Disarm Therapeutics and as an advisor for Atlas Venture. Prior roles have included CSO of Padlock Therapeutics, President & CEO of Euclises Pharmaceuticals, Senior Vice President of Deciphera Pharmaceuticals, Senior Vice President of Jubilant Drug Discovery & Development, and various positions of increasing responsibility at Pfizer and legacy Pharmacia and Searle companies. He received his Ph.D. in Medicinal Chemistry from Duquesne University and completed his Postdoctoral Fellowship at Purdue University.
Mr. Auspitz is a Partner at F-Prime Capital, where he focuses on therapeutics, with a particular interest in Series A and company formation. He is a member of the board of directors of numerous venture-backed biopharmaceutical companies. Before joining F-Prime, he served as Therapeutic Area Head for immuno-inflammatory products at CombinatoRx, Inc., during its growth from an angel-backed start-up to a publicly-listed company. In this role, he oversaw the advancement of seven programs from assay stage into clinical studies and was co-inventor on fifteen product patents. Mr. Auspitz holds a B.A. from Harvard University.
Peter Ruminski, M.S.
Mr. Ruminski is an accomplished pharmaceutical scientist with over 34 years of research experience and a recognized expert in the design of RGD-binding integrin antagonists. He possesses a strong medicinal chemistry and molecular biology background and has extensive experience in the development of drug candidates and in advancing them into human clinical trials. He previously held positions at Monsanto, Searle, Pharmacia, and Pfizer and most recently served as adjunct professor in the department of Biochemistry and Molecular Biology and as Executive Director of the Center for World Health and Medicine at Saint Louis University. Mr. Ruminski received his B.S. in Chemistry from Saint Louis University and his M.S. in Molecular Biology from Washington University in St. Louis.
David Griggs, Ph.D.
Dr. Griggs is a scientific expert in the field of integrin biology with over 20 years of experience managing drug research programs at large pharmaceutical companies (Searle, Pharmacia, and Pfizer) and in a university-based translational pharmacology center (the Center for World Health and Medicine at Saint Louis University). He has led teams that designed and implemented nearly two dozen in vitro integrin functional assays as well as diverse in vivo studies to evaluate efficacy, pharmacology, and safety of RGD-binding integrin antagonists. He received a B.S. degree in Biological Sciences from Northern Kentucky University and M.S. and Ph.D. degrees in Microbiology from the University of Illinois at Urbana-Champaign.